Pharmacological treatment of schizophrenia

International Review of Psychiatry

Volumn 24, Issue 5, 2012, Pages 489-498

  Gadelha, Ary ^a   Noto, Cristiano Souza ^a   De Jesus Mari, Jair ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; BIPERIDEN; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; TRIHEXYPHENIDYL; ZIPRASIDONE; ZUCLOPENTHIXOL;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; AMENORRHEA; ANXIETY; ASTHENIA; BLURRED VISION; CONSTIPATION; DIZZINESS; DRUG INDUCED HEADACHE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; FUNCTIONAL STATUS; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOMANIA; HYPOTENSION; INSOMNIA; LONG TERM CARE; LOWEST INCOME GROUP; MAINTENANCE THERAPY; MENTAL PATIENT; METABOLIC SYNDROME X; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREGNANCY; PRIAPISM; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; RELAPSE; RESTLESSNESS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL INTERACTION; SOCIAL STATUS; SWEATING; TARDIVE DYSKINESIA; TREATMENT RESPONSE; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DEVELOPING COUNTRIES; HUMANS; SCHIZOPHRENIA;

EID: 84867514594     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2012.703643     Document Type: Review

References (67)

1. ADA -AP (2004) . American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes . Obesity Research, 12, 362 - 368.
2. Adams, C.E., Fenton, M.K., Quraishi, S. & David, A.S . (2001). Systematic meta-review of depot antipsychotics drugs for people with schizophrenia . British Journal of Psychiatry, 179, 290 - 299.
3. Alvir, J.M.J., Lieberman, J.A., Safferman, A.Z., Schwimmer, J.L. & Schaaf, J.A . (1993) . Clozapine-induced agranulocytosis: Incidence and risk factor in the United States . New England Journal of Medicine, 329, 162 - 167.
4. Andreasen, N.C., Carpenter, W.T., Kane, J.M., Lasser, R.A., Marder, S.R. & Weinberger, D.R . (2005) . Remission in schizophrenia: Proposed criteria and rationale for consensus . American Journal of Psychiatry, 162, 441-449.
5. APA (2004) . Practice Guideline for the Treatment of Patients with Schizophrenia (2nd ed .) . Washington, DC: American Psychiatric Press
6. Bowie, C.R., Reichenberg, A., Patterson, T.L., Heaton, R.K. & Harvey, P.D . (2006) . Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognitive, functional capacity and symptoms . American Journal of Psychiatry, 163, 418 - 425.
7. Brown, S., Kim, M., Mitchell, C. & Inskip, H . (2010) . Twenty-fi ve year mortality of a community cohort with schizophrenia . British Journal of Psychiatry, 196, 116 - 121.
8. Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., Fischer, B.A., Keller, W . (2010) . Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements . Schizophrenia Bulletin, 36, 71 - 93.
9. Capasso, R.M., Lineberry, T.W., Bostwick, J.M., Decker, P.A. & St Sauver, J . (2008) . Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950 - 2005 . Schizophrenia Research, 98, 287 - 294.
10. Claghorn, J., Honigfeld, G., Abuzzahab, F.S., Wang R, Steinbook, R., Tuason, V. & Klerman, G . (1987) . The risks and benefi ts of clozapine versus chlorpromazine . Journal of Clinical Psychopharmacology, 7, 377 - 384.
11. Correll, C.U., Frederickson, A.M., Kane, J.M. & Manu, P . (2006). Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs . Journal of Clinical Psychiatry, 67, 575 - 83.
12. Crisholm, D., Gureje, O., Saldivia, S., Calderon, M.V., Wickremasinghe, R., Mendis, N., Saxena, S . (2008) . Schizophrenia treatment in the developing world: An interregional and multinational cost-effectiveness analysis . Bulletin of the World Health Organization, 86, 542 - 551.
13. Delay J, Deniker P, Harl JM . (1952). [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)]. Ann Med Psychol (Paris), 110, 112 - 7.
14. Edwards, N.C., Locklear, J.C., Rupnow, M.F.T. & Diamond, R.J. (2005) . Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA . Pharmacoeconomics, 23, S75 - 89.
15. Elkis, H., Gama, C., Suplicy, H., Tambascia I, M., Bressan, R.A., Lyra, R., . .Minicucci, W . (2008) . Brazilian consensus on second- generation antipsychotics and metabolic disorders . Revista Brasileira de Psiquiatria, 30, 77 - 85.
16. Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F. & M öller, H.J . (2005) . WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry, 6, 132 - 191.
17. Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F. & M öller, H.J . (2006) . WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 2: Long-term treatment of schizophrenia. World Journal of Biological Psychiatry, 7, 5 - 40.
18. Geddes, J., Freemantle, N., Harrison, P. & Bebbington, P . (2000). Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis . BMJ, 321, 1371 - 1376.
19. Gentile, S . (2010) . Antipsychotic therapy during early and late pregnancy . A systematic review. Schizophrenia Bulletin, 36, 518 - 544.
20. Grundy, S.M., Brewer, H.B., Cleeman, J.I., Smith, S.C. & Lenfant, C . (2004) . Defi nition of metabolic syndrome: Report of the National, Heart, Lung and Blood Institute/American Heart Association conference on scientifi c issues related to defi nition. Circulation, 109, 433 - 438.
21. Hennekens, C.H., Hennekens, A.R., Hollar, D. & Casey, D.E. (2005) . Schizophrenia and increased risks of cardiovascular disease . American Heart Journal, 150, 1115 - 1121.
22. Hert, M., Dekker, J.M., Wood, D., Kahl, K.G., Holt, R.I.G. & M öller, H.J . (2009) . Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) . European Psychiatry, 24, 412 - 424.
23. Hippius, H . (1999) . A historical perspective of clozapine . Journal of Clinical Psychiatry, 60S12, S22 - 23.
24. Hofer, A., Kemmler, G., Eder, U., Edlinger, M., Hummer, M. & Feischhacker, W.W . (2004) . Quality of life in schizophrenia: The impact of psychopathology, attitude toward medication and side effects . Journal of Clinical Psychiatry, 65, 932 - 939.
25. Huskamp, H.A . (2006) . Prices, profi ts, and innovation: Examining criticisms of new psychotropic drugs ' value . Health Affairs, 25, 635 - 646.
26. International Psychopharmacology Algorithm Project (IPAP). (2006). Schizophrenia Algorithm, Available at www.ipap.org
27. Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., ergouwe, Y., Keet, I.P.M., Gschwandtner, U . (2008) . Effectiveness of antipsychotic drugs in first episode schizophrenia and schizophreniform disorder: An open randomized clinical trial . Lancet, 371, 1085-1096.
28. Kane, J.M . (2008) . An evidence-based strategy for remission in schizophrenia . Journal of Clinical Psychiatry, 69, 25 - 30.
29. Kane, J., Honigfeld, G., Singer, J. & Meltzer, H . (1988) . Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine . Archives of General Psychiatry, 45, 789 - 796.
30. Kapur, S. & Seeman, P . (2001) . Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. American Journal of Psychiatry, 158, 360 - 369.
31. Kapur, S., Zipursky, R., Jones, C., Remington, G. & Houle, S. (2000) . Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of firstepisode schizophrenia . American Journal of Psychiatry, 157, 514 - 520.
32. Klaussen, K.P., Parving, H.H., Schaling, H. & Jensen, J.S . (2007). The association between metabolic syndrome, micoralbuminuria and impaired renal function in the general population: Impact on cardiovascular disease and mortality . Journal of Internal Medicine, 262, 470 - 478.
33. Lambert, M., Conus, P., Eide, P., Mass, R., Karow, A., Moritz, S., . .Naber, D . (2004) . Impact of present and past antipsychotic side effects on attitute toward typical antipsychotic treatment and adherece . European Psychiatry, 19, 415 - 422.
34. Leucht, S., Arbter, D., Engel, R.R., Kissling, W. & Davis, J.M. (2009a) . How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry, 14, 429 - 447.
35. Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C. & Davis, J.M . (2009b) . Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis . Lancet, 373, 31 - 41.
36. Leucht, S. & Heres, S . (2006) . Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia . Journal of Clinical Psychiatry, 67S5, S3 - 8.
37. Leucht, S., Pitschel-Wals, G., Abraham, D. & Kissling, W . (1999). Effi cacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperido, and sertindole compared to conventional antipsychotics and placebo . A meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51 - 68.
38. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, S., Rosenheck, R.A., Perkins, D.O., . .Hsiao, J.K . (2005) . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia . New England Journal of Medicine, 353, 1209 - 1223.
39. Lincoln, T.M., Wilhelm, K. & Nestoriuc, Y . (2007) . Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: A meta-analysis. Schizophrenia Research, 96, 232 - 245.
40. Mari, J.J., Razzouk, D., Thara, R., Eaton, J. & Thornicroft, G. (2009) . Packages of care for schizophrenia in low- and middle-income countries . PLoS Medicine, 6, 10, e1000165. doi:10.1371/journal.pmed.1000165.
41. Masand, P.S., Roca, M., Turner, M.S. & Kane, J.M . (2009) . Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: A review . Primary Care Companion to the Journal of Clinical Psychiatry, 11, 147 - 154.
42. Matza, C.S., Buchanan, R., Purdon, S., Brewster-Jordan, J., Zhao, Y. & Revicki, D.A . (2006) . Measuring changes in functional status among patients with schizophrenia: The link with cognitive impairment . Schizophrenia Bulletin, 32, 666 - 678.
43. McEvoy, J.P., Lieberman, J.A., Stroup, T.S., Davis, S.M., Meltzer, H.Y., Rosenheck, R.A., . .Hsiao, J.K . (2006) . Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment . American Journal of Psychiatry, 163, 600 - 610.
44. McEvoy, J.P., Meyer, J.M. & Goff, D.C . (2005) . Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III . Schizophrenia Research, 80, 19 - 32.
45. Mitchell, A.J. & Lord, O . (2010) . Do defi cits in cardiac care infl uence high mortality rates in schizophrenia? A systematic review and pooled analysis. Journal of Psychopharmacology, 24S4, 69 - 80.
46. Munro, J., O ' Sullivan, D., Andrews, C., Arana, A., Mortimer, A. & Kerwin, R . (1999) . Active monitoring of 12,760 clozapine recipients in the UK and Ireland . Beyond pharmacovigilance. British Journal of Psychiatry, 175, 576 - 570.
47. Nasr, T. & Kausar, R . (2009) . Psychoeducation and the family burden in schizophrenia: A randomized controlled trial . Annals of General Psychiatry, 8, 17 . doi:10.1186/1744 -859X-8-1.
48. NCCMH (2010) Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care . Leicester and London: British Psychological Society and the Royal College of Psychiatrists
49. Newcomer, J.W . (2004 Abnormalities of glucose metabolism associated with atypical antipsychotic drugs Journal of Clinical Psychiatry 65S18 34-46
50. Newcomer, J.W . (2007) . Antipsychotic medications: Metabolic and cardiovascular risk . Journal of Clinical Psychiatry, 68, 8 - 13.
51. NICE (2002) . Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia . London: National Institute for Clinical Excellence
52. Patterson, T.L. & Leeuwenkamp, O.R . (2008) . Adjunctive psychosocial therapies for the treatment of schizophrenia . Schizophrenia Research, 100, 108 - 119.
53. Perkins, D.O . (2002) . Predictor of noncompliance in patients with schizophrenia . Journal of Clinical Psychiatry, 63, 1121 - 1128.
54. RANZCP CPG Team (2005) . Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders . Australian and New Zealand Journal of Psychiatry, 39, 1 - 30.
55. Robinson, D., Woerner, M.G., Alvir, J.M.J., Bilder, R., Goldman, R., Geisle, S., . .Lieberman, J.A . (1999) . Predictors of relapse following response from a first-episode of schizophrenia or schizoaffective disorder . Archives of General Psychiatry, 56, 241 - 247.
56. Rocha, D.M.L.V., Neto, J.B.B., Elkis, H. & Bressan, R.A . (2010). Terap ê utica com clozapina [Treatment with clozapine]. In R.A. Bressan & H. Elkis (Eds), Esquizofrenia refrat á ria [Refractory schizophrenia] (2nd ed.). S ã o Paulo, Segmento Farma
57. Rosenbloom, M . (2002) . Chlorpromazine and psychopharmacologic revolution . Journal of the American Medical Association, 287, 1860 - 1861.
58. Rummel-Kluge, C., Komossa, K., Schwartz, S., Hunger, H., Schmid, F., Lobos, C.A., . .Leucht, S . (2010) . Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis . Schizophrenia Research, 123, 225 - 233.
59. Saha, S., Chant, D. & McGrath, J . (2007) . A systematic review of mortality in Schizophrenia . Archives of General Psychiatry, 64, 1123 - 1131.
60. Shirakawa, I . (2007) . Esquizofrenia: Ades ã o ao tratamento [Schizophrenia: Compliance with treatment]. S ã o Paulo: Casa Editorial Lemos
61. Stahl, S.M . (2011) . Stahl ' s Essential Psychopharmacology: The Prescriber ' s Guide (4th ed .) . New York: Cambridge University Press
62. Üç ok, A., Incesu, C., Aker, T. & Erko ç, S . (2007) . Sexual dysfunction in patients with schizophrenia on antipsychotic medication. European Psychiatry, 22, 328 - 333.
63. Velligan, D.I., Diamond, P.M., Mintz, J., Maples, N., Li, X., Zeber J., . .Miller, A.L . (2008) . The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia . Schizophrenia Bulletin, 34, 483 - 493.
64. Weiden, P.J . (2007) . EPS profi les: The atypical antipsychotics are not the same . Journal of Psychiatric Practice, 13, 13 - 24.
65. Weiden, P.J. & Buckley, P.F . (2007) . Reducing the burden of side effects during long-term antipsychotic therapy: The role of ' switching ' medications . Journal of Clinical Psychiatry, 68, 14 - 23.
66. Weiden, P.J. & Zygmunt, A . (1997) . The road back: Working with severely mentally ill . Medication noncompliance in schizophrenia. Part . 1 : Assessment . Journal of Practical Psychiatry and Behavioral Health, 3, 106 - 110.
67. Young, C.R., Bowers, M.B. Jr & Manure, C.M . (1998) . Management of the adverse effects of clozapine . Schizophrenia Bulletin, 24, 381 - 390.